NewAmsterdam Pharma Company N.V.

NAMS

$25.57

-1.08%

N/A-$0.28

Salud

Biotecnología

NASDAQ

Negociación activa

NewAmsterdam Pharma Company N.V., una compañía biofarmacéutica en fase avanzada, desarrolla terapias para mejorar la atención al paciente en poblaciones con enfermedad ...

Ejecutivos C-Level

(0)

El equipo C-Level forma un liderazgo cohesionado que impulsa la estrategia financiera y la innovación de la empresa.

Miembros clave del equipo

No hay ejecutivos para este nivel

Loading executive datasets...

Founder / CEO

C-Level

Board

Director / Board

Other

Key Executives

Name	Title	Compensation	Gender	Year Born	Status
Michael Harvey Davidson FACC Facp.	CEO, President & Executive Director	USD 1,139,142	—	1956	Active
Johannes Jacob Pieter Kastelein FESC	Founder, Chief Scientific Officer, Member of Executive Board & Director	USD 808,143	—	1954	Active
Douglas F. Kling	Chief Operating Officer	USD 790,051		1973	Active
Mayur Amrat Somaiya	Chief Financial Officer	USD 770,393		1974	Active
Louise Kooij	Chief Accounting Officer	USD 695,419		1976	Active
Juliette Audet	Chief Strategy & Business Officer	USD 653,039		1987	Active
Marc Ditmarsch	Chief Development Officer	—	—	1967	Active
Chris Deluzio	Executive Vice President of Sales Enterprise Operations	—		—	Active
Michael F. Marino	Chief Legal Officer & Corporate Secretary	—		1976	Active
Maryellen McQuade	Chief People Officer	—		—	Active
Matthew Philippe	Executive VP & Head of Investor Relations	—		—	Active

Executive Compensation

(deduped by latest filing date per person-year)

Filing Date	Year	Name	Position	Level	Salary	Bonus	Stock Award	Option Award	Incentive	Other	Total

Total Compensation Trend

Sum of disclosed compensation by year (USD million)

Key Roles Compensation Lines

Top founder/C-level executives over time (USD million)

Supply Chain de NAMS

RELATIONS

Upstream

Piramal Pharma Solutions (Piramal Pharma Ltd)NSE:PPLPHARMAUnnamed CDMO (Canada-based)Unnamed CDMO (Austria-based)Unnamed CDMO (US-based, not Piramal)API Raw Material Suppliers (via Piramal Pharma Solutions network)Ezetimibe API Suppliers (generic drug substance)

Downstream

A. Menarini International Licensing S.A. (Menarini Group)Menarini Group (EU Distribution Network)US Market (Direct Commercialization – Planned)Japan Partner (Phase 2 Study Initiated)

Proxies

Piramal Pharma LtdNSE:PPLPHARMAAmgen Inc.NASDAQ:AMGN Esperion Therapeutics Inc.NASDAQ:ESPR Novartis AGNYSE:NVS

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal